Mirum Pharmaceuticals Inc
MIRM
查看详细走势图
100.470USD
+2.240+2.28%
收盘 02/06, 16:00（美东）报价延迟15分钟
5.16B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.28%
5天
-2.66%
1月
+22.55%
6月
+67.95%
今年开始到现在
+27.19%
1年
+96.77%
查看详细走势图
TradingKey Mirum Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Mirum Pharmaceuticals Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业中等水平。增长潜力很大。当前估值合理，在药品行业排名5/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价114.70。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Mirum Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Mirum Pharmaceuticals Inc亮点
亮点风险
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
业绩高增长
公司营业收入稳步增长，连续3年增长337.16%
估值低估
公司最新PE估值-118.33，处于3年历史低位
机构减仓
最新机构持股59.10M股，环比减少4.41%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值78.12K
活跃度增加
近期活跃度增加，过去20天平均换手率0.72
分析师目标
根据
10
位分析师
买入
评级
114.700
目标均价
+10.33%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Mirum Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Mirum Pharmaceuticals Inc简介
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
公司代码MIRM
公司Mirum Pharmaceuticals Inc
CEOPeetz (Christopher)
网址https://mirumpharma.com/
相关品种
